Showing 5201-5210 of 21466 results for "".
- Perioperative Apalutamide Cuts Metastasis Risk in Proteus Trialhttps://reachmd.com/news/apalutamide-metastasis-risk-proteus/2487349/Key Takeaways The PROTEUS trial met both primary endpoints, with higher pathologic response at surgery and improved metastasis-free survival for the combination regimen. Secondary analyses showed longer time before subsequent therapy and a broader patt
- FRONTIER3: Tozorakimab Shows Signal in Early-Onset Asthmahttps://reachmd.com/news/tozorakimab--frontier3-asthma/2487324/Key Takeaways In the intent-to-treat population, the week 16 primary endpoint was not statistically significant versus placebo. Patients with at least 2 prior exacerbations showed greater improvement in clinic pre-BD FEV1, especially with 600 mg.
- Buntanetap in Mild-to-Moderate Alzheimer’s: Phase 2/3 Study Findingshttps://reachmd.com/news/buntanetap-mild-moderate-alzheimers/2487325/Key Takeaways In the intent-to-treat population, primary endpoints changed similarly in pooled buntanetap and placebo groups; however, post-hoc analyses showed 38% of participants lacked amyloid burden. Buntanetap was well tolerated, with no serious tr
- Study Supports PLLA-SCA for Décolletage Rejuvenationhttps://reachmd.com/news/study-supports-plla-sca-for-decolletage-rejuvenation/2487331/Poly-L-lactic acid for injectable suspension (PLLA-SCA; Sculptra, Galderma) was effective and well tolerated for correction of moderate to severe décolletage wrinkles using either 8-mL or 17-mL reconstitution volumes, according to findings from a 9-month, open-label study published in the Jou
- Headache on the Hill 2026 Recap: Advocacy, Policy Priorities, And Accesshttps://reachmd.com/news/headache-on-the-hill-2026-recap-advocacy-policy-priorities-and-access/2487314/Key Takeaways The event brought together 282 advocates from 47 states, including patients, caregivers, researchers, clinicians, and about 20 youth advocates. The HEADACHE Act, the Safe Step Act, and the CONNECT for Health Act were the highlighted feder
- AHS Preview Highlights New Treatments, Biomarkers, and Gut-Brain Topicshttps://reachmd.com/news/ahs-preview-highlights-new-treatments-biomarkers-and-gut-brain-topics/2487316/Key Takeaways The meeting will bring more than 350 abstracts and five plenary sessions to Orlando from June 4-7, 2026. The highlighted themes are treatment innovation, biomarkers and personalized medicine, and gut-brain axis topics. The schedu
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://reachmd.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Positive NSCLChttps://reachmd.com/news/sacituzumab-tirumotecan-plus-pembrolizumab-in-pd-l1-positive-nsclc/2487321/Key Takeaways Progression-free survival favored the combination on hazard ratio analysis at the prespecified interim review. The progression-free survival advantage was reported as broadly consistent across PD-L1 tumor proportion score subgroups.
- Roche Details ADA 2026 Obesity Portfolio Presentationshttps://reachmd.com/news/roche-details-ada-2026-obesity-portfolio-presentations/2487320/Key Takeaways Roche is previewing late-breaking Phase II data at ADA 2026 for enicepatide from CT388-103 and for petrelintide from ZUPREME-1. Roche says both assets are moving into Phase III development, and a Phase II multi-arm fixed-dose combination
- Skin Cancer Champions Announces Patient Advocacy Summithttps://reachmd.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t